Family · Pharmaceutical analytical standards
Lurasidone
An atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors. Approved in the United States in 2010 for schizophrenia and in 2013 for depression associated with bipolar disorder. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Among second-generation antipsychotics it has the highest affinity for the serotonin 5-HT7 receptor, which is involved in regulating mood, sleep, circadian rhythms and memory.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
